3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
43
Carcinoma, Hepatocellular
19
Rectal Neoplasms
10
Colonic Neoplasms
10
Neoplasm Metastasis
9
Gastrointestinal Stromal Tumors
8
Sarcoma
5
Ovarian Neoplasms
5
Melanoma
4
Cholangiocarcinoma
4
Pancreatic Neoplasms
3
Osteosarcoma
3
Liver Neoplasms
3
Glioblastoma
3
Stomach Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Gallbladder Neoplasms
2
Fatigue
2
Esophageal Neoplasms
2
Colorectal Cancer Metastatic
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Bile Duct Neoplasms
2
Adenocarcinoma
2
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
1
Thyroid Neoplasms
1
Thymoma
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Interventions
Cyclophosphamide
3
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
liposomal doxorubicin
2
Paclitaxel
2
Gemcitabine
2
Doxorubicin
2
Dexamethasone
2
Cisplatin
2
Carboplatin
2
Bortezomib
2
vandetanib
1
umbralisib
1
ublituximab
1
regorafenib
1
pomalidomide
1
pembrolizumab
1
nilotinib
1
marizomib
1
lutetium Lu 177 dotatate
1
grapiprant
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
cemiplimab
1
carotuximab
1
axicabtagene ciloleucel
1
avelumab
1
Thioctic Acid
1
Tamoxifen
1
Receptors, Interleukin-6
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Disease Progression
×
regorafenib
×
Clear all
NCT07514455
2026-04-07
RECOMEND
Asan Medical Center
Phase 2
Not yet recruiting
20 enrolled